Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05125133
Other study ID # ITENs
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 9, 2021
Est. completion date September 30, 2022

Study information

Verified date November 2021
Source Ifakara Health Institute
Contact Zawadi Mboma, PhD
Phone +255 787 428218
Email zmageni@ihi.or.tz
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a household randomized trial of a new tool for house modification, Insecticide-Treated Eave nets (ITENs) in combination with insecticide-treated window screens (ITWS), coated with a dual active ingredient (dual AI): Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m² and PBO synergist at 10g/kg which corresponds to 480 mg/m², as used in the so-called dual-AI LLIN or "resistance breaking" nets for resistance malaria vector control. Four hundred and fifty (450) households with intact walls, opened eaves, and those without screens or nets on the windows in Chalinze district, Tanzania will be eligible and only recruited upon written informed consent. The households will be randomly allocated into two arms: one with ITENs and ITWS installed and the other without. The primary outcome will be malaria parasite detection in household residents aged over 6 months old using a quantitative Polymerase Chain Reaction (qPCR) at approximately 12 months post-installation, coinciding with the long rainy season.


Description:

In Tanzania, long-lasting insecticidal nets (LLINs) contributed to the high reduction of malaria in the last decade. However, malaria reduction in Tanzania is threatened due to increasing insecticidal resistance of malaria vectors, low access to LLIN, LLINs not lasting up to three years, and net usage compliance. Therefore, it is evident that an additional cost-effective vector control tool is required that may confer protection against resistant malaria vectors, protect every member of the household, requires little or less compliance to use after distribution, and lasts longer. The proposed additional vector control tool for trial is the Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification. The tool is coated with a dual active ingredient (dual AI): Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m², and PBO synergist at 10g/kg which corresponds to 480 mg/m², which are coated at the same concentration in insecticide-treated nets that are already in use in the population to control pyrethroid-resistant mosquitoes. These can protect everyone in the house by blocking mosquito entry and killing mosquitos that contact them to protect everyone in the community. In this trial, 450 households will be randomly allocated into two arms. One arm with ITENs & ITWS installed and the other without to serve as the control arm. The 450 households are recruited and assigned codes during baseline data collection. The assigned codes are randomized to either of the two arms by simple randomization in STATA and stratified by sub-village. Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons, clinical officers will screen for malaria parasites in household residents of over 6 months old (it is estimated that 4.4 persons reside in each household, thus approx. 1,800 persons will be screened for malaria per survey) in both arms and confirmation of malaria parasite will be done using qPCR analysis as the primary assessment of the primary outcome. As a point of care, SD Bioline Malaria Ag Pf/Pan rapid diagnostic test (RDT) as per Tanzanian guidelines will also be conducted on all household residents. Any participant (s) with an axillary temperature of 37.5 degrees (fever) and that test positive using mRDT will be considered as a clinical malaria case. All malaria-positive participants will be treated using free Artemether Lumefantrine (ALu). This drug is approved by the national guideline for the treatment of uncomplicated malaria. Other secondary objectives are: - To evaluate malaria prevalence in households with ITENs & ITWS and those without at approximately 6 months post-installation, coinciding with the short rainy season. - To determine the prevalence of clinical malaria defined by an axillary temperature of 37.5 degrees and above (fever) and mRDT malaria positive cases at approximately 6 months and 12 months post-installation, coinciding with the rainy seasons. - To investigate the effect of ITENs and ITWS on the density of malaria vectors and nuisance (Culex quinquefasciatus) mosquitoes in the community at approximately 6 months and 12 months post-installation, coinciding with the rainy seasons using Centres for Disease Control (CDC) light traps. - To assess the number of fabric in meters and time of installing the intervention (feasibility of scaling-up ITENs and ITWS use) in local houses in the field during installation. - To assess the adverse effects of ITENs and ITWS in the community. - To determine the attrition and fabric integrity of ITENs and ITWS in the field post 6 months and 12 months of installation. - To determine the mortality induced by (bioefficacy) ITENs and ITWS on laboratory-reared mosquitoes post 12 months of installation. - To determine the insecticide retainment of ITENs and ITWS post 12 months of installation. - To assess the acceptability of ITENs and ITWS to the local community post 6 months and 12 months of installation.


Recruitment information / eligibility

Status Recruiting
Enrollment 1800
Est. completion date September 30, 2022
Est. primary completion date August 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months and older
Eligibility Inclusion Criteria: - Residents of study households' members. Exclusion Criteria: - None residence. - Pregnant women.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
ITENs + ITWS
A dual active ingredient (dual AI) Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification.

Locations

Country Name City State
Tanzania Vector Control Product Testing Unit Facility Bagamoyo

Sponsors (3)

Lead Sponsor Collaborator
Ifakara Health Institute London School of Hygiene and Tropical Medicine, Swiss Tropical & Public Health Institute

Country where clinical trial is conducted

Tanzania, 

References & Publications (5)

Gleave K, Lissenden N, Richardson M, Choi L, Ranson H. Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. Cochrane Database Syst Rev. 2018 Nov 29;11:CD012776. doi: 10.1002/14651858.CD012776.pub2. U — View Citation

Gnanguenon V, Azondekon R, Oke-Agbo F, Beach R, Akogbeto M. Durability assessment results suggest a serviceable life of two, rather than three, years for the current long-lasting insecticidal (mosquito) net (LLIN) intervention in Benin. BMC Infect Dis. 2014 Feb 8;14:69. doi: 10.1186/1471-2334-14-69. — View Citation

Matiya DJ, Philbert AB, Kidima W, Matowo JJ. Dynamics and monitoring of insecticide resistance in malaria vectors across mainland Tanzania from 1997 to 2017: a systematic review. Malar J. 2019 Mar 26;18(1):102. doi: 10.1186/s12936-019-2738-6. — View Citation

Mboera LE, Mweya CN, Rumisha SF, Tungu PK, Stanley G, Makange MR, Misinzo G, De Nardo P, Vairo F, Oriyo NM. The Risk of Dengue Virus Transmission in Dar es Salaam, Tanzania during an Epidemic Period of 2014. PLoS Negl Trop Dis. 2016 Jan 26;10(1):e0004313. doi: 10.1371/journal.pntd.0004313. eCollection 2016 Jan. — View Citation

Mboma ZM, Overgaard HJ, Moore S, Bradley J, Moore J, Massue DJ, Kramer K, Lines J, Lorenz LM. Mosquito net coverage in years between mass distributions: a case study of Tanzania, 2013. Malar J. 2018 Mar 1;17(1):100. doi: 10.1186/s12936-018-2247-z. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of Plasmodium falciparum parasite. Prevalence of plasmodium falciparum parasite measured by qPCR among residents over 6 months old in houses with ITENs & ITWS compared to houses without. Approximately 12 months post-installation, coinciding with the long rainy season.
Secondary Prevalence of Plasmodium falciparum parasite. Prevalence of plasmodium falciparum parasite in households' residents of over 6 months old with ITENs & ITWS compared to those without using qPCR analysis. Approximately 6 months post-installation, coinciding with the short rainy season.
Secondary Clinical malaria. The prevalence of clinical malaria cases defined by an axillary temperature of 37.5 degrees (fever) and positive mRDT in houses with ITENs and ITWS compared to the houses without. Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
Secondary The density of malaria vectors and nuisance mosquitoes density. Indoor density of malaria vector and nuisance mosquitoes in houses with ITENs & ITWS compared to houses without measured using Centres for Disease Control (CDC) light traps. Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons.
Secondary ITENs & ITWS fabric cost The number of metres of material applied to houses. Baseline (During installation of ITENs & ITWS)
Secondary ITENS & ITWS time duration Time in hours to install the intervention. Baseline (During installation of ITENs & ITWS)
Secondary Adverse effects The number of participants with perceived adverse effects from ITENs and ITWS. Approximately one month post installation.
Secondary Attrition Determination of the physical presence of ITENs and ITWS in the field. Appriximately 6 months and 12 months post installation.
Secondary Fabric integrity Determination of the number of holes in ITENs and ITWS in the field. Appriximately 6 months and 12 months post installation.
Secondary The induced mosquito mortality of ITENs and ITWs on the population of laboratory-reared mosquitoes. The bioefficacy (% induced mosquito mortality) of ITENs and ITWS after field use through WHO bioassays. Approximately 12 months post installation.
Secondary Insecticide retainment The retention of deltamethrin and PBO in grams per kg will be assessed through high performance liquid chromatography. Appriximately 12 months post installation.
Secondary Use of ITENs and ITWS Community opinions of ITENs and ITWS will be sought through questionnaires and Focus Group Discussions. Approximately 6 months and 12 months post installation.
See also
  Status Clinical Trial Phase
Terminated NCT04130282 - VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine Phase 1
Completed NCT04049916 - Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission Phase 2/Phase 3
Active, not recruiting NCT03814616 - Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections Phase 2
Active, not recruiting NCT04079621 - Short Course Radical Cure of P. Vivax Malaria in Nepal Phase 4
Completed NCT05135273 - Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali Phase 1
Not yet recruiting NCT06083688 - Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi Phase 4
Recruiting NCT03511443 - Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections N/A
Completed NCT05550909 - Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali Phase 2
Recruiting NCT05306067 - Plasmodium Falciparum Genomic Intelligence in Mozambique
Completed NCT05081089 - Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali Phase 2
Recruiting NCT05150808 - Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania Phase 3
Recruiting NCT05757167 - Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics Phase 4
Completed NCT01992900 - A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria Phase 2
Completed NCT04565184 - Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde Phase 4
Completed NCT03896724 - Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso Phase 1/Phase 2
Completed NCT03454048 - Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 N/A
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Completed NCT03138096 - Safety and Protective Efficacy of Pb(PfCS@UIS4) Phase 1/Phase 2
Recruiting NCT04271306 - Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania. Phase 1
Recruiting NCT05058885 - Plasmodium Vivax Among Duffy Negative Population in Cameroon.